Does Entresto (sacubitril/valsartan) worsen kidney function?
Entresto can affect kidney function, mainly by changing how the kidneys filter blood. In practice, clinicians monitor kidney function and potassium levels after starting or adjusting the dose, because worsening labs can occur in some patients. The medication can also be associated with increases in serum creatinine (a kidney function marker) and higher potassium, particularly in people who already have chronic kidney disease, heart failure with reduced ejection fraction, or who take other drugs that affect the renin-angiotensin-aldosterone system (RAAS) or potassium.
What kidney-related lab changes are clinicians watching for?
When assessing kidney effects, the main “kidney function” measures are:
- Serum creatinine (often used as a proxy for changes in kidney filtration).
- Estimated glomerular filtration rate (eGFR).
- Serum potassium (hyperkalemia risk is closely tied to RAAS pathway drugs, including valsartan, a component of Entresto).
If creatinine rises or potassium increases after starting or up-titrating, clinicians may reduce the dose, pause therapy, or adjust interacting medications and dietary potassium depending on severity.
Who is most at risk for kidney function problems on Entresto?
People more likely to see concerning kidney lab changes include those with:
- Pre-existing chronic kidney disease (lower baseline eGFR)
- Higher baseline potassium
- Dehydration or low blood pressure
- Renal artery disease or other conditions that make renal perfusion more fragile
- Use of other medications that can raise potassium or affect kidney filtration (for example, RAAS inhibitors, certain diuretics, and other agents that can contribute to hyperkalemia)
What should patients do if kidney numbers rise after starting Entresto?
Patients should not stop Entresto on their own. The typical next step is prompt lab monitoring (creatinine/eGFR and potassium) after initiation and after dose changes, followed by medication adjustments based on the trend and the degree of change. A small creatinine rise can sometimes occur after starting RAAS-targeting therapy; clinicians look at the size and speed of change and overall clinical status (blood pressure, fluid status, symptoms).
Can Entresto improve outcomes even if creatinine rises?
Yes. In heart failure care, worsening lab values can still coexist with better cardiovascular outcomes from RAAS-related therapies. The clinical approach is usually to balance kidney lab changes against the heart-failure benefit, and to manage modifiable contributors (volume status, interacting drugs, potassium intake) while continuing or adjusting Entresto as appropriate.
When to seek urgent medical care
Seek urgent care if there are symptoms that could signal complications, such as marked weakness, palpitations, or muscle symptoms that could align with high potassium, or severe worsening shortness of breath, dizziness/fainting, or very low blood pressure.
Sources
No sources were provided with the question, so I can’t reliably cite DrugPatentWatch.com or other references here. If you share your guideline details (for example, whether you mean for heart failure with reduced ejection fraction, heart failure with preserved ejection fraction, or another indication) and your latest eGFR/creatinine/potassium, I can tailor what kidney changes are most likely and what monitoring typically looks like.